Abiopharma

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting

MIND Technology / GWL Collaboration Agreement

New Form 6-K - KAMADA LTD Filed: 2025-06-17 AccNo: 0001213900-25-054947 Size: 22 KB

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria

Unicycive Therapeutics, Inc. Announces Reverse Stock Split

Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer

Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson’s Disease

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

New Form 6-K - Haleon plc Filed: 2025-06-17 AccNo: 0001654954-25-007079 Size: 51 KB

New Form 6-K - Haleon plc Filed: 2025-06-17 AccNo: 0001654954-25-007077 Size: 36 KB

New Form 6-K - GSK plc Filed: 2025-06-17 AccNo: 0001654954-25-007075 Size: 2 MB

New Form SC 14D9/A - Regulus Therapeutics Inc. Filed: 2025-06-17 AccNo: 0001104659-25-060054 Size: 43 KB

New Form SC TO-T/A - Regulus Therapeutics Inc. Filed: 2025-06-17 AccNo: 0001104659-25-060052 Size: 24 KB

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma